Innate Pharma : Expansion of the collaboration with Sanofi
>Payments that could reach € 1.3bn - Innate Pharma announced this morning that it had entered into a new agreement with Sanofi to expand their collaboration around NK cell engagers. With this expansion, Sanofi obtains an exclusive licence for 1/ the development and commercialisation of a multi-specific antibody stemming from the ANKET platform targeting B7H3 and 2/ an option to add up to 2 additional targets from the platform.Sanofi will be responsible for the de...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.